VEGFA and hereditary clear cell renal cell carcinoma: Keefe et al. [42] investigated patients with metastatic or locally advanced unresectable renal cell carcinoma who received a median of two prior therapies, including at least one prior vascular endothelial tyrosine kinase inhibitor therapy (VEGF-TKI).